Fundamental analysis · SEC EDGAR · TTM through 30/06/2026
BSX · NYSE · Healthcare
Fundamental quality
83
out of 100
Boston Scientific Corp grows profitably: it increases revenue at double digits (14.6% a year) without giving up profitability (net margin 17.5%). On fundamental quality it scores 83 out of 100, profiling it as a company with solid fundamentals. Whether it's cheap or expensive depends on the current price, which you can compute in the tool.
Boston Scientific makes minimally invasive medical devices: stents, catheters, pacemakers and tools for cardiology, endoscopy and urology. Its products are used in millions of procedures a year in hospitals worldwide.
EPS growth: 32.8% · Revenue growth: 14.6%
Net margin: 17.5% · ROE: 14.7% · ROIC: 10.7%
Net debt/EBITDA: 2.17x · FCF: 17.3%
Source: SEC EDGAR · TTM through 30/06/2026
The score combines growth, profitability and financial strength, and here its pillars hold up evenly.
Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).
Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.
Key concepts
What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2020 | 9,913 | -82 | 1,132 | 7,409 |
| 2021 | 11,888 | 1,041 | 1,316 | 7,140 |
| 2022 | 12,682 | 698 | 938 | 8,007 |
| 2023 | 14,240 | 1,592 | 1,792 | 8,237 |
| 2024 | 16,747 | 1,846 | 2,645 | 10,332 |
| 2025 | 20,074 | 2,892 | 3,658 | 9,471 |
Between 2020 and 2025, revenue went from $9,913M to $20,074M (+103%) and net income went from -$82M to $2,892M (+3627%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Latest results
Figures for the half-year ended June 30, 2026, versus the half-year ended June 30, 2025 (SEC filings):
Compared with the previous close (March 31, 2026), this is what moved in its accounts:
Automatic comparison between the two most recent periods filed with the SEC. One quarter doesn't make a trend: read it alongside the historical evolution above.
This company doesn't pay a dividend: it reinvests all its earnings back into the business.
Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.
The serious investor's standard
Open free account →Anyone who wants low commissions and access to almost any market in the world.
Popular in the U.S.
Open free account →Anyone investing in the U.S. who wants a powerful, commission-free stock app.
Investing carries risk of loss.
Is Boston Scientific Corp cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Is Boston Scientific Corp a good company to invest in?
In terms of business quality, Boston Scientific Corp scores 83 out of 100 in our analysis, placing it as a company of high fundamental quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.
Is Boston Scientific Corp a profitable company?
Yes. Boston Scientific Corp shows a net margin of 17.5% and an ROE of 14.7%, a sign of a profitable business.
Does Boston Scientific Corp have a lot of debt?
A moderate level: its net debt is 2.17 times its EBITDA.
Is Boston Scientific Corp growing?
Its revenue has grown 14.6% annualized in recent years and its earnings per share 32.8%, and without interruption since 2020.
Does Boston Scientific Corp generate cash?
Yes. It converts about 17.3% of its revenue into free cash flow, and has done so positively year after year.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
More Healthcare companies
Idexx Laboratories (IDXX) · Dexcom (DXCM) · IQVIA (IQV) · Agilent Technologies (A) · ResMed (RMD) · West Pharmaceutical (WST) · see more →
The best Healthcare stocks by our model →
Compare Boston Scientific Corp with 500+ companies in the screener →
Who's behind the methodology and model · how the score is computed
Data: see Boston Scientific Corp's filings on EDGAR
Spotted a figure that looks wrong? Report it and we'll review it.